Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.
See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.
Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.
Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.
Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

| TITLE/ COMPANY | Issue Date | Status | Details |
|---|---|---|---|
| Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process. RC Outsourcing, LLC |
03 Sep 2026 | Normal | Justification: Process validation involves ensuring all aspects of production meet standards; deficiencies in AFV and media fill undermine this validation. Excerpt: No formal study reports or supporting documentation were available for review for either study. View Details |
| Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic and sterilization process Imprimis NJOF, LLC |
18 Aug 2026 | Normal | Justification: Observation highlights insufficient sterilization validation, fundamental to process validation ensuring aseptic environments. Excerpt: Procedures designed to prevent microbiological contamination did not include adequate validation of the aseptic and sterilization process. View Details |
| Your firm failed to establish written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess. Imprimis NJOF, LLC |
18 Aug 2026 | Normal | Justification: Inadequate Process Validation highlighted by missing (b)(4) compatibility studies during critical qualification phase. Excerpt: The firm does not have a procedure governing the process for (b)(4) compatibility studies and has not conducted (b)(4) compatibility studies. View Details |
| Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity Neeyaan LLC |
07 Aug 2026 | Normal | Justification: Process validation is essential for verifying that manufacturing processes achieve consistent product quality. The observation highlights a failure in conducting such validation. Excerpt: You failed to demonstrate your drug manufacturing processes are adequately validated. Additionally, you manufactured and released (b) (4) lots of (b) (4) USP tablets in 2025 intended for export. Your firm stated that no process validation was conducted for this product. View Details |
| OBJECTIVE 1e: The proposed commercial process and manufacturing batch record, including instructions Not available |
29 Jun 2026 | Normal | Justification: Process validation is essential for establishing the feasibility of manufacturing operations using scientifically justified data. The observation notes a lack of sufficient validation studies. Excerpt: At a minimum, data from Stage I process validation should be available. Evaluate Stage I process validation development studies and knowledge gained. View Details |
View and learn more about FDA Inspections
with our comprehensive list of resources